1. Home
  2. BANR vs NVAX Comparison

BANR vs NVAX Comparison

Compare BANR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banner Corporation

BANR

Banner Corporation

HOLD

Current Price

$64.40

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$6.77

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANR
NVAX
Founded
1890
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.1B
IPO Year
1995
1995

Fundamental Metrics

Financial Performance
Metric
BANR
NVAX
Price
$64.40
$6.77
Analyst Decision
Buy
Hold
Analyst Count
6
8
Target Price
$71.20
$9.75
AVG Volume (30 Days)
190.3K
3.1M
Earning Date
01-21-2026
11-06-2025
Dividend Yield
3.10%
N/A
EPS Growth
14.84
N/A
EPS
5.49
2.07
Revenue
$640,027,000.00
$1,064,651,000.00
Revenue This Year
$0.96
$58.91
Revenue Next Year
$7.48
N/A
P/E Ratio
$11.77
$3.30
Revenue Growth
7.86
20.27
52 Week Low
$54.01
$5.01
52 Week High
$72.58
$11.55

Technical Indicators

Market Signals
Indicator
BANR
NVAX
Relative Strength Index (RSI) 46.84 47.05
Support Level $66.40 $6.36
Resistance Level $67.95 $7.00
Average True Range (ATR) 1.24 0.20
MACD -0.32 0.06
Stochastic Oscillator 3.91 65.63

Price Performance

Historical Comparison
BANR
NVAX

About BANR Banner Corporation

Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: